Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “positive” rating restated by FBR & Co in a research report issued on Wednesday.
ABEO has been the topic of a number of other reports. Cantor Fitzgerald initiated coverage on Abeona Therapeutics in a research note on Wednesday, September 7th. They issued a “buy” rating and a $21.00 target price on the stock. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 12th. Rodman & Renshaw reaffirmed a “buy” rating and set a $17.00 price objective on shares of Abeona Therapeutics in a research report on Sunday, August 21st. Finally, Maxim Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Abeona Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.00.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded up 12.962% during midday trading on Wednesday, reaching $6.789. The company had a trading volume of 621,848 shares. The company has a 50 day moving average of $5.00 and a 200 day moving average of $3.33. Abeona Therapeutics has a 12-month low of $2.05 and a 12-month high of $7.00. The firm’s market capitalization is $227.74 million.
Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. Analysts anticipate that Abeona Therapeutics will post ($0.73) EPS for the current year.
In other news, Director Todd Wider bought 5,000 shares of the company’s stock in a transaction on Tuesday, September 20th. The shares were acquired at an average cost of $5.48 per share, with a total value of $27,400.00. Following the completion of the transaction, the director now owns 75,000 shares of the company’s stock, valued at approximately $411,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 13.00% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ABEO. Geode Capital Management LLC boosted its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares during the last quarter. Sabby Management LLC boosted its position in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the last quarter. Finally, Royce & Associates LP boosted its position in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares during the last quarter. 19.95% of the stock is currently owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.